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ABSTRACT 
Objective: This work aims to formulate and evaluate an ophthalmic in-situ gel of ciprofloxacin hydrochloride (HCl) using poloxamer 407 (P407) as 
a gelling agent and hydroxypropyl methylcellulose (HPMC) as a viscosity modifier. The objective of this work was to prolong the contact time as the 
in-situ gel will be converted into a gel upon contact with the cul-de-sac.  
Methods: Ciprofloxacin HCl ophthalmic in-situ gel was prepared by utilizing (P407) as a temperature-dependent polymer while hydroxypropyl 
methylcellulose was used as a viscosity modifier. The system was evaluated for physical appearance, pH, drug content, sterility, irritancy and 
stability. In addition, gelation temperature and a viscosity at different shear rates and different temperatures were studied. The compatibility of the 
polymer with ciprofloxacin was studied by using fourier transform infrared spectroscopy (FTIR). The in vitro release of the drug was also evaluated 
and supported by a preliminary in vivo test. 
Results: The results showed that the prepared formulas were clear, with acceptable pH and the drug contents were within the acceptable limits. 
FTIR results detected no incompatibility between poloxamer 407 and ciprofloxacin HCl. Notably, the viscosity of the system showed a pseudoplastic 
behaviour where a reduction in viscosity upon increasing the shear rate was observed. The in vitro release study confirmed the prolongation of the 
release of the optimized formula (F6) up to 8 h. Upon application of F6 into eyes of rabbits there was no irritancy. In addition, in vivo elimination 
study showed a prolonged contact for the in-situ gel in comparison with the rapid clearance of eye drop. Stability study indicated the stability of the 
optimized formula (F6).  
Conclusion: The prepared optimized formula (F6) represents a successful, safe, stable and prolonged release in-situ gel formula of ciprofloxacin.  
Keywords: Ophthalmic in-situ gel, Poloxamer, Ciprofloxacin HCl, Solution-gel transition 




The most common and well-accepted route of administration for the 
treatment of many eye conditions is the topical application of drugs 
to the eye. Blinking, baseline and reflex lachrymation, and drainage 
remove foreign ingredients, including drugs, from the surface of the 
eye. Furthermore, the physiology, anatomy and barrier role of the 
cornea decreases the rapid absorption of drugs [1]. The exceptional 
anatomical and physiological nature and protective mechanisms of 
the eye make the targeting of drugs to eye tissues one of the most 
extreme challenges in drug delivery [2]. A substantial task for the 
formulator is to avoid the defensive barriers of the eye without 
causing permanent tissue impairment [3].  
Formulation of ophthalmic drug delivery systems has many 
challenges, but also offers many prospects to overcome the 
insufficiencies of the present formulations. As a result of the 
restricted area and time for absorption in the eye, the residence time 
of most conventional ocular solutions is 5–25 min and only 1–10% 
of the topically applied drug is absorbed [2]. In addition to the 
various protective mechanisms, the corneal epithelium has a 
compound hydro-and lipophilic character that limits drug 
absorption. The conjunctiva plays an important role in drug 
elimination from the ocular surface due to its rich blood flow, large 
surface area and more permeable membrane compared to the 
corneal membrane. There is consequently a need for the recurrent 
instillation of eye drops, which is accompanied by distress and a 
reduction in patient compliance, especially in long-term therapy [4].  
Therefore, an increase in the contact time between dosage form and 
the corneal surface is required to overcome these difficulties. This 
can be achieved by gelling systems. In-situ gelling systems can be 
defined as viscous liquids, which undergo a phase transition from 
solution to gel when applied to the human body. The triggers to 
phase change are either temperature, pH or ionic strength. In-situ 
gelling systems permit precise and reproducible administration of a 
drug not like preformed gels and are capable of extending the 
formulation's residence time to the mucosal surface due to post-
instillation gelling [5]. 
The most common polymers used in the formulation of in-situ gel 
include poloxamer, carbopol and alginates polymers for 
temperature-dependent, pH-dependent, and ionic-dependent 
systems respectively.  
Poloxamer 407 (P407) or what is known commercially as Pluronic® 
F-127 consists of about 70% ethylene oxide, which accounts for its 
hydrophilicity. P407 is a 12,000-Da copolymer; it is non-toxic, liquid 
at 4 °C and converts to a semisolid gel at body temperature [6]. P407 
is common in ophthalmic use, where it is changed into a colorless, 
optically clear and transparent gel at temperatures above 35 °C [2]. 
P407 molecules aggregate into micelles when the temperature rises. 
This micellization is the very first step in the gelling process which 
occurs owing to the dehydration of hydrophobic propylene oxide 
blocks. The dehydrated polyoxypropylene form the core of the 
spherical micelles while the outer shell contains hydrated swollen 
polyoxyethylene chains. Then as temperature increases further, 
gelation occurs for sufficiently concentrated samples [7]. 
Ciprofloxacin hydrochloride (HCL) (fig. 1) is a potent broad-
spectrum antibiotic of fluoroquinolones, the in vitro antibacterial 
activity is greater than other antibiotics. Additionally, ciprofloxacin 
has an effective topical antibiotic activity with a low frequency of 
spontaneous resistance, therefore, it is a favorable drug for the 
treatment of bacterial keratitis [8]. 
This work aims to formulate and evaluate a thermo-sensitive ocular in-
situ gel of ciprofloxacin HCl using poloxamer 407 (P407) as a gelling 
agent and hydroxypropyl methylcellulose (HPMC) as a viscosity 
modifier. Visual appearance, clarity, pH and sol-gel transition 
temperature of formulas were tested. Comprehensive rheological 
properties of the prepared formula were also studied. In addition, 
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irritancy test of the best formula was assessed. The release of the drug 
was studied by using in vitro dissolution test. In order to study the 
retention of the gel in the eye, a pioneer work was conducted using an 
auto refractometer apparatus to track the contact time of ciprofloxacin 
gel in comparison to marketed eye drop of ciprofloxacin. In addition, 
sterility test and stability test were also conducted. 
 
 
Fig. 1: The chemical structure of ciprofloxacin hydrochloride [9] 
 
MATERIALS AND METHODS 
Materials 
Ciprofloxacin hydrochloride was kindly supplied by Pioneer 
company for pharmaceutical industry (Sulaymania, Iraq), 
Pluronic®F-127 (P407) (Sigma Aldrich CO. USA), hydroxypropyl 
methylcellulose (HPMC) (HIMEDIA), sodium chloride (Akzonobel, 
Denmark), sodium bicarbonate (Solvay, Germany), Calcium chloride 
dihydrate (VIGROUS Group, China), Sodium acetate (Merck, 
Germany), Fluorescein sodium ophthalmic strips U. S. P. (OptiGlo, 
India). All other chemicals were of analytical grade. 
Preparation of the in-situ gels 
Twelve different formulas of ciprofloxacin HCl in-situ gel were 
prepared by using different concentrations of (P407) with different 
concentrations of HPMC (table 1). 
An in-situ gel of ciprofloxacin was prepared by using the cold 
method [10]. The required amount of (P407) was added to acetate 
buffer (pH 4.5) (at 4 °C) with gentle mixing and then allowed to 
hydrate overnight at the same temperature. The required amount of 
viscosity enhancing agent, HPMC, was dissolved in hot acetate buffer 
and cooled to 4 °C and then added to polymer solutions. 
Ciprofloxacin HCl was dissolved in the required amount of acetate 
buffer and then sodium chloride and benzalkonium chloride were 
added to the solution. After that, the drug solution was added to the 
polymer solution and mixed. 
The samples were then transferred to vials and stored in a 
refrigerator overnight. Finally, the vials were sterilized by autoclave 
at 121 °C at 15 psi for 20 min.  
 
Table 1: Composition of ophthalmic in-situ gels of ciprofloxacin hydrochloride % (w/w) 
Formulas Ciprofloxacin HCl (P407) HPMC Benzalkonium chloride Sodium chloride equivalent to 
F1 0.3 15 0.2 0.02 0.9 
F2 0.3 15 0.4 0.02 0.9 
F3 0.3 15 0.6 0.20 0.9 
F4 0.3 16.25 0.2 0.02 0.9 
F5 0.3 16.25 0.4 0.02 0.9 
F6 0.3 16.25 0.6 0.02 0.9 
F7 0.3 17.5 0.2 0.02 0.9 
F8 0.3 17.5 0.4 0.02 0.9 
F9 0.3 17.5 0.6 0.02 0.9 
F10 0.3 20 0.4 0.02 0.9 
F11 0.3 16.25 0 0.02 0.9 
F12 0.3 17.5 0 0.02 0.9 
 
Evaluation of the in-situ gel 
Clarity and pH 
All prepared formulas were evaluated for clarity by visual 
observation against a black and white background [11]. pH was 
measured using digital pH meter (Mettler Toledo/Germany).  
Drug content 
The drug content was determined by taking 0.2 ml of the formula 
and completing the volume to 100 ml with acetate buffer pH 4.5. 
Ciprofloxacin concentration was then detected by measuring the 
absorbance at 278 nm by using UV-Vis spectrophotometer (Specord 
50, analytic Jena/Germany). 
Fourier transform infrared spectroscopy (FTIR) 
FTIR spectrometer (Thermo Scientific, USA) was used to record the 
FT-IR spectra of ciprofloxacin, P407 and their physical mixture. 
Sufficient amount (2–4 mg) of the sample was placed to form a thin 
film covering the diamond window. 
Measurement of the solution-gel transition temperature  
Tube tilting method was used to measure gelation temperature [12]. 
Two millilitres of the refrigerated formula were transferred to a test 
tube. The tube was maintained in a thermostatically controlled digital 
water bath (memmert, Germany) at 4 °C. The temperature of the water 
bath was increased gradually in increments of 3 °C at the beginning of 
the experiment and then 1 °C increments in the region of sol-gel 
transition temperature (25–34 °C) and 0.1 °C when it approaches 
gelation. The gelation was considered to occur when the meniscus of the 
formula would no longer move upon tilting through a 90 ° angle [13]. 
Gelling capacity  
The gelling capacity was determined by placing one drop of the 
formula in a test tube containing 2 ml of freshly prepared simulated 
tear fluid (STF) and equilibrated at 37 °C and visually assessing the 
formation of a gel, noting the time for gelation and the time taken for 
the formed gel to be dissolved [14]. STF composed of NaCl-0.67 g, 
NaHCO3-0.20 g, CaCl2 2H2O-0.008 g and distilled water to 100g [15]. 
Rheological studies 
Rheological properties of the prepared ciprofloxacin HCl in-situ gels 
were measured using viscometer EZ-lock spindle coupling helipath 
stand (Brookfield Engineering Laboratories Inc., Model DV2T, USA) 
connected to a digital thermostatically controlled circulating water 
bath with spindle SC4-18. The viscosity was determined for each 
sample at a different shear rate and temperature. The angular 
velocity increased gradually from 0.1 to 50 rpm while the 
temperature increased from 22 to 36 °C. 
Sterility test 
Sterility test was intended for identifying the presence of viable 
microorganisms and performed for aerobic/anaerobic bacteria and 
fungi by using fluid thioglycolate medium and soybean-casein digest 
medium. Two ml of the formula were withdrawn with a sterile syringe 
then aseptically transferred to thioglycolate medium and soybean-
casein digest medium separately. The inoculated media were 
incubated for 14 d at 30-35 °C in case of fluid thioglycolate medium 
and at 20-25 °C in case of soybean-casein digest medium [16]. 
In vitro drug release study 
A modified dissolution test was used for evaluating the in vitro release 
profile [17]. A glass cylinder (2.3×8 cm in dimensions), open at both 
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ends, was used for the purpose of the study. Whatman® membrane 
previously soaked overnight in STF was taken and tied to one end of 
the cylinder by using parafilm and an elastic ring. One ml of the 
formula was accurately added on the membrane. Further, the glass 
cylinder was fixed to the shaft of USP apparatus I, in place of the 
basket. The cylinder was then suspended in the release medium (200 
ml) maintained at 37±0.5 °C in a way that the membrane just touched 
the release medium. The speed of the device shaft was set at 50 rpm. 
Aliquots were withdrawn at different time intervals of 0.5, 1, 2, 3, 4, 6, 
8 and 10 h and compensated by equal volumes of dissolution medium 
after each withdrawal. Aliquots were filtered and then analyzed by UV 
spectrophotometer at 272 nm. The cumulative percentage of drug 
released was calculated and plotted against time.  
Ocular irritancy test 
Ocular irritation studies were conducted on 3 healthy female Newzeland 
albino rabbits weighing 1.5-2 kg. They are obtained from the animal’s 
house in veterinary college/university of Mosul (animal studies were 
approved by the postgraduate specialist committee in the college of 
pharmacy/university of Mosul, approval no. 12/2017-1). The animals, 
housed in an air-conditioned and in a light-controlled room at 20±1 °C 
and 50±5% R. H., were given a standard diet and water. The modified 
Draize technique [18] was designed for measuring the ocular irritation 
potential of the ophthalmic product. One drop of optimized in-situ gel 
formula was placed in the lower cul-de-sac of the left eye while the right 
eye left untreated and considered as a negative control. The rabbits' eyes 
were tested periodically after a different time interval of 1 h, 2 h, 24 h, 48 
h, and 72 h after administration of treatment. Both eyes were checked by 
an ophthalmologist for redness, swelling and watering. 
In vivo fluorescein tracking study 
To reach the goal of studying the elimination time of the in-situ gels, 
fluorescein sodium salt was dispersed in the marketed eye drop and 
F6 by using fluorescein sodium ophthalmic strips U. S. P. (OptiGlo, 
India). One drop of each preparation was added into the lower 
conjunctival sac of rabbit (n = 3), an autorefractometer (Huvitz, 
Korea) with blue light was used to monitor the disappearance of the 
fluorescein sodium salt. At selected time intervals the eyes were 
examined, when only a minute amount or none of the gel remained it 
was considered as lost from the eye. The preceding time for the 
check was defined as the elimination time. 
Stability study 
The stability of the optimized in-situ gel was conducted on the 
selected formula (F6). Ten ml of (F6) formula was stored in closed 
amber color glass vials at different conditions, that is, refrigerated 
condition (5±2 °C), room temperature (23±2 °C) and stress 
condition, i.e. high temperature (40±2 °C, 75% RH). The sample was 
withdrawn at a predetermined time interval, that is, 6 and 12 w and 
the clarity, pH and drug content were analysed. 
Statistical analysis 
The experimental data were analyzed using Origin software (version 
8.0, OriginLab), one-way Analysis of Variance (ANOVA) test was 
applied and a p-value of less than 0.05 was considered as the 
required level of significance (n = 3). 
RESULTS AND DISCUSSION 
Clarity and pH 
Non-transparent formulations might blur the vision and are not 
tolerable by the patient. So clarity is an extremely desirable 
characteristic in ophthalmic formulations. All prepared ciprofloxacin 
HCl in-situ gel formulas were clear and transparent. The pH values of 
all formulas were found to be between 4.57 and 4.72 as shown in 
table 2. These values comply with pharmacopeial requirements [19]. 
Drug content 
The drug content of all formulas was in the range of (94.01-
102.59%) as shown in table 2 which is in compliant with the 
requirement of the assay (90-110%) [19]. 
Fourier transform infrared spectroscopy (FTIR) 
FTIR results showed no detected chemical interaction between 
ciprofloxacin HCl and P407. Fig. 2 shows that there were no extra 
peaks appearing and no noticed shift in peaks when comparing the 
IR chart of ciprofloxacin alone (fig. 2, a), the IR chart of poloxamer 
alone (fig. 2, b) with the IR chart of the physical mixture of 
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Fig. 2: FTIR spectra for ciprofloxacin hydrochloride (a), poloxamer 407 (P407) (b), and the physical mixture of ciprofloxacin HCl and 
poloxamer 407 (ciprofloxacin-P407PM) (c) 
 
Measurement of the gelation temperature 
The best in-situ gel ocular system should be liquid with low viscosity 
at room temperature (around 23 °C) to facilitate administration into 
the eye as drops. However, at physiological temperature (37 °C) it 
should undergo a phase change into a gel in the ocular cul-de-sac to 
prolong drug release. The formulas produced using 15% P407 failed 
to form a gel at physiological temperature. Using higher 
concentrations of P407; 16.25% (F4, F5, F6 and F11), 17.5% (F7, F8, 
F9 and F12) and 20% (F10) produced clear gel (table 2). Fig. 3 
shows the viscosity changes in consequence with gel-forming when 
the temperature has been increased from 22 to 34 °C. 
 
 
Fig. 3: Phase change or solution-gel transition at different 
temperatures. Values represent mean±SD. (n = 3) 
 
A relationship between gelation temperature and the concentration 
of P407 was noticed as demonstrated in (fig. 4); when poloxamer 
407 concentration increases there was a significant reduction in 
gelation temperature (*p less than 0.05). This is consistent with 
many works [20–23]. Park et al. found a linear relationship between 
P407 concentration and sol-gel transition temperature over a 
concentration range of 10-25%; the transition temperature is 
linearly reduced when P407 concentration has been increased [24]. 
Having more effective concentration of P407 retain a higher number 
of micelles to be contained in formulas. As a result, they would need 
lesser energy to promote sol-gel transition and this lead to achieve a 




Fig. 4: Gelation temperature of different concentrations of 
poloxamer 407, values represent mean±SD. (n = 3)
 
Table 2: Evaluation parameters of various formulas of ocular in-situ gels of ciprofloxacin hydrochloride 




F1 4.64±0.01 Clear transparent No gel up to 40 + 100.69±0.08 
F2 4.64±0.00 Clear transparent No gel up to 40 + 94.01±0.02 
F3 4.63±0.01 Clear transparent No gel up to 40 + 96.91±0.11 
F4 4.61±0.00 Clear transparent 31.5±0.3 ++ 95.5±0.06 
F5 4.66±0.00 Clear transparent 31.1±0.1 +++ 96.06±0.06 
F6 4.57±0.00 Clear transparent 30±0.01 +++ 98.35±0.11 
F7 4.72±0.00 Clear transparent 26.8±0.2 +++ 94.2±0.03 
F8 4.72±0.03 Clear transparent 26.3±0.1 +++ 99.53±0.01 
F9 4.72±0.01 Clear transparent 25.9±0.3 +++ 102.59±0.02 
F10 4.72±0.00 Clear transparent 22±0.1 ++++ 99.3±0.22 
F11 4.63±0.00 Clear transparent 31.6±0.05 ++ 101.7±0.04 
F12 4.65±0.01 Clear transparent 26.8±0.1 +++ 97.4±0.03 
Note: +, Viscous solution formed after a few minutes, dissolves rapidly; ++, Immediate gelation and remains for few hours (moderate gelling 
capacity); +++, Immediate gelation and remains for extended period (high gelling capacity);++++,viscous gel, n=3; Data are expressed as mean ± SD. 
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The gelling capacity of all formulas is presented in table 2. Formulas 
F1 to F3, which were prepared with low concentrations of 
poloxamer (15%), formed viscous solution after a few minutes 
which dissolves rapidly. However, formulas with higher 
concentrations of poloxamer (F4-F12) showed immediate gelation 
and remained as a gel for an extended period of time. The ideal 
formula should undergo a rapid gelation in the ocular cul-de-sac and 
the gel formed in-situ should reserve its integrity without eroding or 
dissolving for an extended period of time [25]. F5-F12 showed high 
gelling capacity except for F11, which shows moderate gelling 
capacity. This might be attributed to that F11 contains no HPMC. 
Rheological study 
Fig. 5 presents the effect of different concentrations of poloxamer on 
the viscosity of the system. As the P407 concentration increases, 
there is an increase in viscosity. This may be due to the fact that 
poloxamer is nonionic polyoxyethylene–polyoxypropylene–polyoxy-
ethylene triblock copolymer molecules that aggregate into micelles 
at 34 °C due to the dehydration of the polymer blocks with 
temperature. The gel formation is a result of micellar expansions and 
packing, and the gel is more entangled at greater poloxamer 
concentrations. As a result of these entanglements, micelles cannot 
separate easily from each other, consequently, a gel containing high 
concentrations of poloxamer would have rigidity and high viscosity 
[26, 27]. Similar observations were found by Mai et al. and W. Lihong 
et al. who observed that the viscosity of poloxamer in-situ gel 
increased by increasing the concentration of P407 [26, 28]. 
Metoprolol tartrate ophthalmic gels, which prepared by Abou el Ela 
et al. found that the gels containing 30% P407 showed a higher 
viscosity than that of 25% [27]. 
It is important to detect whether the rheological behavior of the 
formula is Newtonian or non-Newtonian. The formulas encoded F1 
to F6, F11 and F12 exhibit Newtonian behavior at 22 °C (i.e. non-
physiological condition) while at 36 °C (i.e. physiological condition), 
they show non-Newtonian shear thinning effect as shown in fig. 6. As 
the ocular shear rate, ranging from 0.03 s-1 during inter-blinking 
periods to 4250–28,500 s-1during blinking, the formula has 
pseudoplastic shear thinning property under high stress is often 
favored [29, 30]. Accordingly, high viscosity under the low shear rate 
and low viscosity under the high shear rate can increase contact 
time and decrease eye irritation after instillation. 
It is worthy to note that F8, F9, and F10 showed non-Newtonian 
behavior at both physiological and non-physiological conditions. 
This might be due to the relatively high concentration of P407 used 
in these formulas. Varshosaz et al. found that increasing in the 
concentration of P407 up to 30% lead to gels display a non-




Fig. 5: Viscosity of in-situ gel at different poloxamer 
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Fig. 6: Viscosity versus shear rate of all formulas at 22 °C and 36 °C. (n=3, Data presented as mean) 
 
In addition, fig. 7 shows that the increment in temperature leads to 
increase in viscosity and the temperature at which viscosity displays 
a significant increment is noted as the gelation temperature [32]. 
When the temperature is increased, hydration of the polymer is 
gradually debilitated and polymer-polymer associations become 
more obvious, thus resulting in the formation of a gel with an 
increase in viscosity [33] 
Effect of HPMC on the viscosity 
The viscosity modifier, HPMC, was used in different concentrations. 
Fig. 7 shows the effect of HPMC on viscosity. It is clear that 
increasing HPMC concentration leads to increase in viscosity of the 
formula. This may be due to the fact that block copolymer P407 
thermo sensitive gels are supposed to be formed by hydrogen 
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bonding in aqueous systems, caused by the attraction of the 
poloxamer ether oxygen atom with protons of water. The number of 
hydrogen bonds is estimated to increase by adding compounds with 
hydroxyl groups such as cellulose derivative (HPMC), thus resulting 




Fig. 7: Viscosities at 0.1 rpm of different poloxamer formulas at different temperatures. (a) 15% poloxamer formulas with 0.2, 0.4 and 0.6 % 
of HPMC for F1, F2 and F3 respectively. (b) 16.25% poloxamer formulas with 0, 0.2, 0.4 and 0.6 % of HPMC for F11, F4, F5 and F6 respectively. 
(c) 17.5% poloxamer formulas with 0, 0.2, 0.4 and 0.6 % of HPMC for F12, F7, F8 and F9 respectively. (n=3, Data presented as mean) 
 
In vitro drug release study 
The cumulative percentage of ciprofloxacin HCl release profiles for 
various in-situ gel formulas in STF is shown in fig. 8a. As the 
formulas prepared with 16.25 % expressed good gelling capacity, 
they were subjected to a further test of in vitro release. All tested 
formulas exhibited prolonged release.  
In case of F4 and F11 about 50% of the ciprofloxacin HCl was 
released into the medium within 30 min, and then about 80% was 
released in 8 h.  
F5 and F6 showed about 80% and 83% release in 8 h, respectively, 
while about 40% of ciprofloxacin HCl was released within 30 min for 
both of them.  
Remarkably, F12 shows longer release pattern, where about 38% of 
the ciprofloxacin HCl was released into the medium within 30 min, 
and then about 77% in 8h. F12 was prepared with 17.25% 
poloxamer and this might be the reason for the slow release of this 
formula. From the results, it is possible to conclude that when the 
concentration of P407 increased from 16.25 to 17.5%, the amount of 
the drug released was reduced. These results show that the 
structure of the gel works as an increasingly resistant barrier to 
drug release as the concentration of P407 increased. The mechanism 
for such increased resistance may possibly be due to a decrease in 
the number and dimensions of water channels and an increase in the 
number and size of micelles inside the gel structure. The shorter 
intermicellar distance result in larger numbers of cross-links 
between neighboring micelles leading to greater viscosity and a 
lower rate of drug release [34]. This assumption may be supported 
by the rheology study which shows direct proportionality between 
P407 concentration and viscosity. 
Fig. 8b shows that in comparison to the marketed eye drop solution, 
where almost all the ciprofloxacin HCl was released immediately 
within 10 min, the selected formula (F6) manifested prolonged 
release. This result indicates that in-situ gel formulation has 
prolonged-release effect in vitro in comparison to the low 
bioavailable, marketed formulation of ciprofloxacin eye drop. 
Ocular irritation test 
The result of eye irritation test of F6 in rabbits, studied by using 
modified Draize test, showed that there was no conjunctival redness 
or edema, no corneal opacity, no secretion and no iris involvement. 
Applying criteria adapted from Asasutjarit et al. for ocular irritation 
evaluation [35], showed that F6 did not irritate the rabbits’ eyes 
since the total score of an eye irritation assessment was zero. 
Therefore, F6 can be considered safe for ophthalmic administration. 
 
 
Fig. 8: Cumulative percentage drug release of different formulas. 
(a) Drug release from formulas prepared with 16.25% poloxamer 
in presence of different concentrations of HPMC (b) Drug release 
from the selected formula (F6) in comparison to the marketed 
eye drop. n=3; Data are expressed as mean±SD 
 
In vivo fluorescein tracking study 
Fluorescein was used in tracking the presence of gel in comparison 
to solution drop. As demonstrated in (fig. 9 a), in-situ gel, which is 
applied in the left eye, remained within the eye and slowly 
disappeared as the gel was cleared. While for the control right eye, a 
solution eye drop was applied (fig. 9 b), where a continuous 
drainage of fluorescein towards the inner canthus along the eyelid 
margin was seen. Thus, elimination of solution in rabbit right eye 
and gel in rabbit left eye was completed within 10 min and 60 min, 
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respectively. This result is even better than that obtained by Song et 
al. (2013) where the percorneal retention was improved from 10 
min in case of the solution to 25 min in case of in-situ gel [36]. 
Improvement in percorneal retention time will lead to improved 
local bioavailability, reduce dose frequency and concentration and 
may improve patient compliance. 
Sterility test 
The formula F6 passed the test for sterility since there was no 
appearance of turbidity and no sign of microbial growth when 
incubated for 14 d at 30-35 °C in case of fluid thioglycolate medium 
and at 20-25 °C in case of soybean-casein digest medium. 
 
 
Fig. 9: In vivo elimination study, fluorescein sodium salt was dispersed in the preparations and visualized using an auto-refractometer. 
One drop of each preparation was added into the lower conjunctival sac of rabbit, an auto-refractometer with blue light was used to 
monitor and photograph the disappearance of the fluorescein sodium salt. (a) Elimination time after the in-situ gel was dropped. (I–VI: 5, 
10, 20, 30, 40, 60 min). (b) Elimination time after the control marketed eye drop was dropped. (I–III: 5, 7.5, 10 min). n=3 
 
Stability test 
Formula 6 showed acceptable stability as shown in table 3, the drug 
content of formula 6, when stored at 4 °C and at room temperature 
for 3 mo, showed no significant variations (*p less than 0.05). In 
addition, the physical appearance of formula F6 when stored in a 
refrigerator and at room temperature did not change. However, F6 
became gel after 3 mo of storage at 40 °C. The pH of F6 when stored 
at 4 °C and at room temperature showed no significant variations 
while when stored at 40 °C there was a significant variation (*p less 
than 0.05). This variation in the pH can be attributed to the 
dehydration of the gel formula. 
  
Table 3: Stability of optimized formula F6 at different conditions 
 0 w 6 w 12 w 
pH Clarity Drug content pH Clarity Drug content pH Clarity Drug content 
4 °C 4.57±0.0 clear 98.35±0.11 4.6±0.01 clear 98.2±0.0 4.62±0.1 Clear sol 98.01±0.1 
25 °C 4.57±0.0 clear 98.35±0.11 4.63±0.0 clear 98.7±0.2 4.63±0.0 Clear sol 97.9±0.06 
40 °C 4.57±0.0 clear 98.35±0.11 5.11±0.01 clear 103.1±0.0 5.41±0.0 Gel formed Not measured 
n=3; Data are expressed as mean±SD. 
 
CONCLUSION 
Ciprofloxacin, a broad-spectrum antibacterial agent used in the 
treatment of ocular infections, was successfully formulated as 
thermo-sensitive ophthalmic in-situ gel using poloxamer 407 as a 
gelling agent in combination with HPMC as a viscosity-enhancing 
agent. Upon instillation into the eye as drops, the formula undergoes 
gelation in the cul-de-sac. The formed gel expressed prolonged in 
vitro drug release over 8 h period. The optimized formula (F6) 
represents a promising alternative to the conventional eye drops 
due to its ability to enhance availability through its prolonged drug 
release and longer precorneal residence time. In addition, the ease of 
administration and the expected reduced frequency of 
administration will result in better patient compliance. 
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